|
FierceBiotech
@
FierceBiotech
Washington, DC
|
|
Tweets by the Fierce Life Sciences editorial team. Subscribe to our daily email newsletter at fiercebiotech.com/offer/signup
|
|
|
23.982
Tweetovi
|
620
Pratim
|
79.801
Osobe koje vas prate
|
| Tweetovi |
|
FierceBiotech
@FierceBiotech
|
18 h |
|
Glenmark officially unveiled Ichnos in October. Its headquarters, as well as a development site, are in Paramus, New Jersey, but it maintains R&D sites overseas fiercebiotech.com/biotech/novart…
|
||
|
|
||
|
FierceBiotech
@FierceBiotech
|
19 h |
|
Some of that cash will be used to help boost the launch of Palforzia, but it’s immediately eyeing the future, spending a mere $10 million upfront, with $385 million in biobucks wedded to it, to license Xencor’s XmAb7195. fiercebiotech.com/biotech/armed-…
|
||
|
|
||
|
FierceBiotech
@FierceBiotech
|
19 h |
|
Regeneron has previously applied its antibody discovery capabilities to pathogens including Ebola and Middle East respiratory syndrome coronavirus (MERS-CoV). fiercebiotech.com/biotech/after-…
|
||
|
|
||
|
FierceBiotech
@FierceBiotech
|
20 h |
|
This comes as thre Big Pharma is splitting into two companies: fiercebiotech.com/biotech/gsk-cu…
|
||
|
|
||
|
FierceBiotech
@FierceBiotech
|
20 h |
|
Lyon, France-based MaaT is one of a clutch of drug developers trying to treat disease by restoring the microbiome. fiercebiotech.com/biotech/maat-b…
|
||
|
|
||
|
FierceBiotech
@FierceBiotech
|
4. velj |
|
Passage ended 2019 with $158.9 million in the bank and now expects its phase 1/2 gangliosidosis trial to kick off in the second half of 2020, with trials for the dementia and Krabbe candidates to follow in the first half of 2021 fiercebiotech.com/biotech/after-…
|
||
|
|
||
|
FierceBiotech
@FierceBiotech
|
4. velj |
|
Bio Fund III dwarfs its two predecessors, which totaled $650 million together. And that’s not all—a16z has built a team around its biotech and healthcare efforts. fiercebiotech.com/biotech/a16z-u…
|
||
|
|
||
|
FierceBiotech
@FierceBiotech
|
4. velj |
|
Vanda publicly framed its lawsuit against the FDA as a stand against “unnecessary animal research.” fiercebiotech.com/biotech/fda-wi…
|
||
|
|
||
|
FierceBiotech
@FierceBiotech
|
4. velj |
|
She comes to the company half a year after Humphrey, who had headed up immuno-oncology at AstraZeneca and Eli Lilly, made her exit. fiercebiotech.com/biotech/after-…
|
||
|
|
||
|
FierceBiotech
@FierceBiotech
|
4. velj |
|
BioMotiv, an accelerator linked to the $340 million Harrington Project for Discovery & Development, teamed up with Bristol-Myers in September. fiercebiotech.com/biotech/bristo…
|
||
|
|
||
|
FierceBiotech
@FierceBiotech
|
4. velj |
|
Bio Fund III dwarfs its two predecessors, which totaled $650 million together. And that’s not all—a16z has built a team around its biotech and healthcare efforts. fiercebiotech.com/biotech/a16z-u…
|
||
|
|
||
|
FierceBiotech
@FierceBiotech
|
3. velj |
|
Insmed licensed INS1007 from AstraZeneca in October 2016 for $30 million upfront and $120 million in milestones down the line. fiercebiotech.com/biotech/insmed…
|
||
|
|
||
|
FierceBiotech
@FierceBiotech
|
3. velj |
|
Gilead publicly floated the idea of using remdesivir to treat the coronavirus, dubbed 2019-nCoV, 10 days ago. Since then, the effort to advance the drug in the indication has gathered pace. fiercebiotech.com/biotech/gilead…
|
||
|
|
||
|
FierceBiotech
@FierceBiotech
|
3. velj |
|
Craig Basson joins the early-stage private biotech after serving at the Swiss Big Pharma for a decade fiercebiotech.com/biotech/boston…
|
||
|
|
||
|
FierceBiotech
@FierceBiotech
|
3. velj |
|
CEPI is supporting programs to develop coronavirus vaccines underway at groups including Inovio Pharmaceuticals and Moderna. The agreement with GSK positions CEPI to expand the support it can offer partner organizations fiercebiotech.com/biotech/gsk-ma…
|
||
|
|
||
|
FierceBiotech
@FierceBiotech
|
31. sij |
|
VX-961 fell at the first hurdle. On Vertex’s fourth-quarter results conference call with investors, Reshma Kewalramani, the company’s chief medical officer, said the phase 1 showed VX-961 lacked the desired pharmacokinetic and tolerability profile. fiercebiotech.com/biotech/vertex…
|
||
|
|
||
|
FierceBiotech
@FierceBiotech
|
31. sij |
|
Chutes & Ladders—Ex-Takeda exec Ivarsson joins Moderna as CDO fiercebiotech.com/biotech/chutes…
|
||
|
|
||
|
FierceBiotech
@FierceBiotech
|
31. sij |
|
The bad news? These percentages drop for both women and people of color as you look up the ranks. Women make up 30% of executive teams and 18% of biotech company board members, while those numbers are 15% and 14% for people of color, respectively. fiercebiotech.com/biotech/we-can…
|
||
|
|
||
|
FierceBiotech
@FierceBiotech
|
30. sij |
|
At the bottom of page 17 of its financial presentation, released as part of its full-year/Q4 results, are three experimental drugs stuck at the bottom of table with a big red arrow pointing down: Translation, they’ve been cut. fiercebiotech.com/biotech/eli-li…
|
||
|
|
||
|
FierceBiotech
@FierceBiotech
|
30. sij |
|
Ivarsson joins Moderna as it drives its hefty pipeline forward. One would think that with 21 programs, Moderna has its hands full. But it looks like the mRNA biotech is planning to build out its pipeline even more. fiercebiotech.com/biotech/ex-shi…
|
||
|
|
||